Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Basic): 2009-2024

Historic EPS (Basic) for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$0.09.

  • Lineage Cell Therapeutics' EPS (Basic) fell 550.00% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 141.67%. This contributed to the annual value of -$0.09 for FY2024, which is 25.00% up from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' EPS (Basic) is -$0.09, which was up 25.00% from -$0.12 recorded in FY2023.
  • Lineage Cell Therapeutics' EPS (Basic)'s 5-year high stood at -$0.09 during FY2024, with a 5-year trough of -$0.26 in FY2021.
  • Its 3-year average for EPS (Basic) is -$0.12, with a median of -$0.12 in 2023.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' EPS (Basic) slumped by 85.71% in 2021, and later skyrocketed by 42.31% in 2022.
  • Lineage Cell Therapeutics' EPS (Basic) (Yearly) stood at -$0.14 in 2020, then plummeted by 85.71% to -$0.26 in 2021, then skyrocketed by 42.31% to -$0.15 in 2022, then grew by 20.00% to -$0.12 in 2023, then rose by 25.00% to -$0.09 in 2024.